🇺🇸 [F-18]-Fludeoxyglucose in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Aspartate Aminotransferase Increased — 1 report (10%)
2. Blood Lactate Dehydrogenase Increased — 1 report (10%)
3. Chest Pain — 1 report (10%)
4. Drug Ineffective — 1 report (10%)
5. Interstitial Lung Disease — 1 report (10%)
6. Lymphocyte Percentage Decreased — 1 report (10%)
7. Multi-Organ Failure — 1 report (10%)
8. Pneumonia — 1 report (10%)
9. Pyrexia — 1 report (10%)
10. Septic Shock — 1 report (10%)

Source database →

Frequently asked questions

Is [F-18]-Fludeoxyglucose approved in United States?

[F-18]-Fludeoxyglucose does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for [F-18]-Fludeoxyglucose in United States?

University of Saskatchewan is the originator. The local marketing authorisation holder may differ — check the official source linked above.